# A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

> **NCT01281514** · PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** carboplatin
- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01281514
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-14
- **Primary completion:** 2018-01-08
- **Final completion:** 2018-01-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281514, "A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01281514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*